The FDA approved a new DARZALEX FASPRO combination therapy for newly diagnosed multiple myeloma patients who are not eligible ...
Multiple Myeloma (MM) research is at the forefront of personalized medicine, driven by rapid advancements in laboratory genomics and molecular diagnostics.
STUDIO CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today welcomed Stephen L. Houff, MD, as the newest member of the IMF Board of Directors.
Darzalex Faspro is a subcutaneous formulation that combines daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase.
Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...
Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...
D-VRd is the only quadruplet regimen approved for patients with newly diagnosed multiple myeloma, irrespective of transplant ...
The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide ...
Johnson & Johnson received approval from the Food and Drug Administration for a treatment for certain patients with multiple myeloma, an incurable form of blood cancer.
Stocktwits on MSN
JNJ stock rises on fresh FDA approval for multiple myeloma drug
The latest approval marks the twelfth indication for Darzalex Faspro and fifth in newly diagnosed multiple myeloma. ・The ...
The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...
The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results